NASDAQ : RVMD
Revolution Medicines, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 190.27 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 40.78B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 41.00B |
| Enterprise Value | 38.26B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 214.34M |
| Shares Outstanding | 214.34M |
| Shares Change (YoY) | +10.45% |
| Shares Change (QoQ) | +6.46% |
| Owned by Insiders (%) | 2.17% |
| Owned by Institutions (%) | 90.23% |
| Float | 184.61M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 58.87 |
| PB Ratio | 15.73 |
| P/TBV Ratio | 16.17 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 11.38 |
| Quick Ratio | 11.12 |
| Debt / Equity | 0.46 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -27.42 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -79.09% |
| Return on Assets (ROA) | -30.12% |
| Return on Invested Capital (ROIC) | -33.68% |
| Return on Capital Employed (ROCE) | -41.00% |
| Weighted Average Cost of Capital (WACC) | 11.73% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.00M |
| Employee Count | 883 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.40 |
| 52-Week Price Change | +229.73% |
| 50-Day Moving Average | 199.22 |
| 200-Day Moving Average | 156.04 |
| Relative Strength Index (RSI) | 48.75 |
| Average Volume (20 Days) | 1,943,684 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 12.93M |
| Short Previous Month | 11.93M |
| Short % of Shares Out | 6.03% |
| Short % of Float | 7.01% |
| Short Ratio (days to cover) | 5.55 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | -1.30B |
| Operating Income | -1.63B |
| Pretax Income | -1.77B |
| Net Income | -1.77B |
| EBITDA | -1.62B |
| EBIT | -1.63B |
| Earnings Per Share (EPS) | -$8.92 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 3.94B |
| Total Debt | 1.19B |
| Net Cash | 2.75B |
| Net Cash Per Share | $12.82 |
| Equity (Book Value) | 2.61B |
| Book Value Per Share | 12.16 |
| Working Capital | 3.67B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -1.22B |
| Capital Expenditures | -9.10M |
| Depreciation & Amortization | 9.06M |
| Net Borrowing | 487.07M |
| Free Cash Flow | -1.23B |
| FCF Per Share | -$5.75 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -10.45% |
| Shareholder Yield | -10.45% |
| Earnings Yield | -4.66% |
| FCF Yield | -3.00% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $258.84 |
| Price Target Difference | 35.30% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 25 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |